Table 2. Economic analysis of aflibercept per VIEW at our department vs ranibizumab in three different treatment regimens.
| Dosing protocol | Year 1 VIEW | Treat-and-extend | PRN | Monthly |
|---|---|---|---|---|
| Drug | Aflibercept | Ranibizumab | Ranibizumab | Ranibizumab |
| Cost of drug per intravitreal injection (£) | 816.00 | 742.00 | 742.00 | 742.00 |
| Mean number of doses per year | 7 | 10.1 | 8.6 | 12 |
| Mean number of outpatient visits with OCT, VA and IVI (£245) | 3 | 10.1 | 8.6 | 12 |
| Mean number of outpatient visits with OCT and VA (£127) | 0 | 0 | 3.4 | 0 |
| Mean number of outpatient visits with VA (£118) | 4 | 0 | 0 | 0 |
| Total mean cost of treatment (£) | 6919.00 | 9968.70 | 8920.00 | 11 844.00 |
Abbreviations: IVI, intravitreal injection; OCT, optical coherence tomography; PRN, Pro Re Nata; VA, visual acuity.